4D Molecular Therapeutics Inc. Experiences Surge in Stock Following Positive Clinical Trial Results
On August 1, 2025, shares of 4D Molecular Therapeutics, Inc. (FDMT) experienced a significant surge in the stock market following the announcement of positive results from a clinical trial focused on diabetic macular edema (DME). The company, which specializes in developing therapies for genetic diseases, saw its stock price increase by over 26% to $5.69 in premarket trading, as reported by Nasdaq.
The rally was triggered by the release of promising 60-week data from the Phase II SPECTRA clinical trial. The trial evaluated the efficacy of 4D-150, a treatment for DME, which is a common complication of diabetes that can lead to vision loss. The results demonstrated that 4D-150 was well tolerated with no intraocular inflammation observed at any timepoint or dose level. Moreover, the treatment showed durable and dose-dependent clinical activity, with sustained gains in visual acuity and anatomic control.
A key highlight from the trial was the Phase 3 dose (3E10 vg/eye) achieving a clinically meaningful 78% reduction in treatment burden compared to the projected on-label aflibercept 2mg every eight weeks. This significant reduction in treatment frequency is a promising development for patients, potentially improving adherence and outcomes.
The European Medicines Agency (EMA) has aligned with the proposed single Phase 3 clinical trial being acceptable, further bolstering investor confidence in the company’s future prospects.
Earlier in the day, multiple sources, including Benzinga, Investing.com, and Finanznachrichten, reported on the positive DME trial results, contributing to the stock’s upward momentum. The news was also highlighted in pre-market movers, with FDMT being one of the top performers.
As of July 30, 2025, 4D Molecular Therapeutics had a close price of $4.5, with a 52-week high of $17.41 and a low of $2.235. The company’s market capitalization stood at approximately $208.46 million.
These developments mark a significant milestone for 4D Molecular Therapeutics as it continues to advance its pipeline of therapies aimed at addressing unmet medical needs in genetic diseases. Investors and stakeholders are closely watching the company’s progress as it moves towards further clinical trials and potential regulatory approvals.